Subtopic Deep Dive
JAK2 V617F Mutation in Myeloproliferative Neoplasms
Research Guide
What is JAK2 V617F Mutation in Myeloproliferative Neoplasms?
The JAK2 V617F mutation is a somatic gain-of-function point mutation at codon 617 of the JAK2 gene that drives constitutive activation of JAK-STAT signaling in the majority of patients with polycythemia vera and essential thrombocythemia myeloproliferative neoplasms.
First identified in 2005, this mutation occurs in over 95% of polycythemia vera cases and 50-60% of essential thrombocythemia and primary myelofibrosis patients (Královics et al., 2005; 3422 citations). It enables precise molecular diagnosis per WHO classifications updated in 2008 and 2016 (Vardiman et al., 2009; 4374 citations; Arber et al., 2016; 9991 citations). Approximately 1500 papers reference JAK2 V617F in MPN diagnostics and treatment contexts.
Why It Matters
JAK2 V617F testing guides precision diagnosis of MPNs, distinguishing polycythemia vera from reactive erythrocytosis and enabling risk-stratified therapy (Arber et al., 2016). Allele burden correlates with thrombotic risk and treatment response, informing prognostication in essential thrombocythemia (Královics et al., 2005). Ruxolitinib, a JAK1/2 inhibitor, targets this mutation's downstream effects, reducing splenomegaly and symptoms in myelofibrosis as shown in phase 3 trials (Harrison et al., 2012).
Key Research Challenges
Allele Burden Quantification
Accurate measurement of JAK2 V617F allele burden requires sensitive qPCR or NGS methods to predict thrombosis risk and therapy response. Variability in assay sensitivity across labs complicates standardization (Královics et al., 2005). Over 50 studies highlight discordance between peripheral blood and bone marrow burdens.
Triple-Negative MPN Identification
Patients lacking JAK2 V617F, CALR, or MPL mutations challenge diagnosis and prognostication. CALR mutations define a subset with indolent course in JAK2-negative cases (Klampfl et al., 2013; 1929 citations). Identifying rare drivers like TET2 remains critical (Delhommeau et al., 2009).
Mutation Functional Consequences
Distinguishing homozygous vs heterozygous JAK2 V617F impacts disease phenotype and progression to myelofibrosis. Exon 12 mutations represent a distinct polycythemia vera variant (Scott et al., 2007; 1233 citations). Integrating clonal evolution data with cardiovascular risk is unresolved (Jaiswal et al., 2017).
Essential Papers
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian et al. · 2016 · Blood · 10.0K citations
Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identi...
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman, Jüergen Thiele, Daniel A. Arber et al. · 2009 · Blood · 4.4K citations
Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the...
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
Róbert Královics, Francesco Passamonti, Andreas Buser et al. · 2005 · New England Journal of Medicine · 3.4K citations
A high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
Siddhartha Jaiswal, Pradeep Natarajan, Alexander J. Silver et al. · 2017 · New England Journal of Medicine · 2.4K citations
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP), which is defined as the presence of an expanded somatic blood-cell clone in persons without other hematologic abnormalities, is c...
The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing Li, Maorong Fu et al. · 2021 · Signal Transduction and Targeted Therapy · 2.2K citations
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl, Heinz Gisslinger, Ashot S. Harutyunyan et al. · 2013 · New England Journal of Medicine · 1.9K citations
Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR. The clinical course in these patients...
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · 2012 · New England Journal of Medicine · 1.8K citations
Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role fun...
Reading Guide
Foundational Papers
Start with Královics et al. (2005; NEJM, 3422 citations) for mutation discovery, Vardiman et al. (2009; Blood, 4374 citations) for WHO integration, and Harrison et al. (2012; NEJM, 1754 citations) for therapeutic validation.
Recent Advances
Study Arber et al. (2016; Blood, 9991 citations) for updated classifications and Jaiswal et al. (2017; NEJM, 2448 citations) for cardiovascular implications.
Core Methods
Core techniques include allele-specific PCR for V617F detection, NGS for clonal burden, and phospho-STAT5 flow cytometry to confirm pathway activation (Královics et al., 2005; Scott et al., 2007).
How PapersFlow Helps You Research JAK2 V617F Mutation in Myeloproliferative Neoplasms
Discover & Search
PapersFlow's Research Agent uses searchPapers('JAK2 V617F allele burden MPN') to retrieve 500+ papers, citationGraph on Královics et al. (2005) to map foundational discoveries, and findSimilarPapers to uncover exon 12 variants like Scott et al. (2007). exaSearch handles nuanced queries on WHO diagnostic criteria from Arber et al. (2016).
Analyze & Verify
Analysis Agent employs readPaperContent on Harrison et al. (2012) to extract ruxolitinib response data by JAK2 status, verifyResponse with CoVe to cross-check allele burden correlations against 20 papers, and runPythonAnalysis for survival curve meta-analysis from polycythemia vera cohorts using pandas and matplotlib. GRADE grading scores evidence from WHO revisions as high-quality.
Synthesize & Write
Synthesis Agent detects gaps in triple-negative MPN therapies post-CALR discovery (Klampfl et al., 2013), flags JAK2-CALR mutual exclusivity contradictions, and generates exportMermaid diagrams of clonal hierarchy. Writing Agent uses latexEditText for diagnostic algorithm revisions, latexSyncCitations to integrate 50 MPN papers, and latexCompile for publication-ready reviews.
Use Cases
"Extract survival data from JAK2 V617F positive polycythemia vera cohorts and plot Kaplan-Meier curves"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Královics 2005, Arber 2016) → runPythonAnalysis (pandas survival analysis, matplotlib plots) → researcher gets CSV-exported curves with GRADE-verified statistics.
"Draft WHO-compliant diagnostic flowchart for JAK2 V617F in essential thrombocythemia"
Research Agent → citationGraph (Vardiman 2009) → Synthesis Agent → gap detection → Writing Agent → latexGenerateFigure (flowchart) → latexSyncCitations → latexCompile → researcher gets PDF with 30 citations.
"Find GitHub repos analyzing JAK2 mutation NGS pipelines from MPN papers"
Research Agent → searchPapers('JAK2 NGS MPN') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets 5 verified pipelines with variant calling scripts.
Automated Workflows
Deep Research workflow conducts systematic review of 100+ JAK2 papers: searchPapers → citationGraph → DeepScan (7-step verification) → structured report on allele burden thresholds. Theorizer generates hypotheses on JAK2-CALR co-occurrence from Klampfl et al. (2013) and Scott et al. (2007). DeepScan analyzes ruxolitinib trials with CoVe checkpoints (Harrison et al., 2012).
Frequently Asked Questions
What is the JAK2 V617F mutation?
JAK2 V617F is a valine-to-phenylalanine substitution at codon 617 causing constitutive JAK2 kinase activation in 95% of polycythemia vera and 50-60% of essential thrombocythemia cases (Královics et al., 2005).
What diagnostic methods detect JAK2 V617F?
WHO guidelines recommend allele-specific qPCR on peripheral blood or bone marrow, with sensitivity >1% variant allele frequency; NGS confirms in triple-negative cases (Arber et al., 2016; Vardiman et al., 2009).
What are key papers on JAK2 V617F?
Královics et al. (2005; NEJM, 3422 citations) discovered the mutation; Scott et al. (2007; 1233 citations) described exon 12 variants; Harrison et al. (2012; 1754 citations) validated ruxolitinib targeting.
What open problems exist in JAK2 V617F research?
Challenges include standardizing allele burden assays, defining progression risk in low-burden carriers, and therapies for JAK2-negative MPNs with CALR or TET2 drivers (Klampfl et al., 2013; Delhommeau et al., 2009).
Research Myeloproliferative Neoplasms: Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching JAK2 V617F Mutation in Myeloproliferative Neoplasms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers